Figure 6.
MS-OVA therapy in combination with checkpoint inhibitor therapy significantly improves survival outcome. C57BL/6 mice were given 5 × 105 B16-OVA tumor cells s.c. in the dorsal flank; 3, 8, and 18 days later 20 μg MS-OVA was injected s.c. at the base of the tail away from the tumor site. In total 100 μg αCTLA-4 (Clone 9D9) was given s.c. alongside the archaeosome vaccination. Then, 250 μg each of αPD-1 (clone: RMP1-14) and αPD-L1 (clone: 10F.9G2) was given i.p on days 9, 12, 15, and 18. Log-rank Mantel Cox test, *** p < 0.001. This study was repeated to confirm results.